Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug behemoth Merck (NYSE:MRK) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Merck and see what CAPS investors are saying about the stock right now.

Merck facts

Headquarters (founded)

Whitehouse Station, N.J. (1891)

Market Cap

$132.4 billion



Trailing-12-Month Revenue

$47.8 billion


Chairman/CEO Kenneth Frazier
CFO Peter Kellogg

Return on Equity (average, past 3 years)



$18.1 billion / $19.6 billion

Dividend Yield



GlaxoSmithKline (NYSE:GSK)
Novartis (NYSE:NVS)
Pfizer (NYSE:PFE)

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 93% of the 2,883 members who have rated Merck believe the stock will outperform the S&P 500 going forward.

Earlier today, one of those Fools, TMFCane, succinctly summed up the Merck bull case for our community:

Januvia and Janumet are poised to explode with the diabetes market. Suvorexant and odanacatib both look good, and keeping all its divisions together (rather than spinning them off a la Abbott and Pfizer) should allow Merck to capitalize on growth segments. This company's done well in compensating for Singulair's loss.

If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. 

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.